Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy

Journal of Gastroenterology

Volumn 35, Issue 11, 2000, Pages 864-869

  Kaneki, Toshimichi ^a   Koizumi, Tomonobu ^a   Kawashima, Akira ^a   Tsushima, Kenji ^a   Kubo, Keishi ^a   Fujimoto, Keisaku ^a   Honda, Takayuki ^a   Akamatsu, Taiji ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemotherapy; Cisplatin (CDDP); Colorectal cancer; Complete remission; Irinotecan (CPT 11); Lung cancer

Indexed keywords

CISPLATIN; IRINOTECAN;

AGED; ARTICLE; ASCENDING COLON; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COLON ADENOCARCINOMA; COLON CANCER; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG EFFICACY; HOARSENESS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MULTIPLE CANCER; OCCULT BLOOD; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; COLONIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS, MULTIPLE PRIMARY;

EID: 0033675682     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350070025     Document Type: Article

References (22)

1. A phase III trial of 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer
2. 5-Fluorouracil plus low-dose leukovorin in the treatment of advanced colorectal cancer
3. Randomized trial of irinotecan versus fluorouracil by continous infusion after fluorouracil failure in patients with metastatic colorectal cancer
4. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
5. Irinotecan as second-line treatment for unresectable liver metastases of colon cancer
6. A case of recurrent advanced colon cancer treated with CPT-11 for second line chemotherapy
7. New vistas for leucovorin in cancer chemotherapy
8. Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer
9. DNA topoisomerase 1 inhibitors
10. Clinical pharmacology of camptothecins
11. Diversity of DNA topoisomerases 1 and inhibitors
12. The development of combination therapy involving camptothecins: A review of pre-clinical and early clinical studies
13. An overview of topoisomerase 1-targeting agents
14. The clinical pharmacology of topoisomerase 1 inhibitors
15. Clinical pharmacokinetics of camptothecin topoisomerase 1 inhibitors
16. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung
17. Effect of combination chemotherapy of low dose CDDP, continous infusion of 5-FU, and intermittent CPT-11 administration for two advanced pancreatic cancer cases with liver metastasis
18. Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in
19. Preventive effects of hange-shasin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in rat
20. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer
21. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats
22. Mobilization of peripheral blood stem cells in patients with advanced thoracic malignancies after irinotecan (CPT-11) administration